Tyra Biosciences Inc. (TYRA)
NASDAQ: TYRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TYRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.39B
- EPS (TTM)
- -$2.63
- Dividend yield
- None
- 52-week range
- 18.25 – 40.65
- Day range
- 19.62 – 20.44
- Volume / Avg
- 467.58K / 852.56K
- Beta
- —
- Shares outstanding
- 69.08M
52-week range
TYRA stock today
Shares of Tyra Biosciences (TYRA) finished higher on Nov 20 at $20.12, a gain of 1.98% or $0.39 per share, versus the S&P 500's 3.70% decline. At this level, TYRA sits near the bottom of its 52-week range of $18.25 to $40.65: 50.5% below the high, set on Apr 1, 2026 and 10.2% above the low. TYRA is down 23.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 4.7%.
Tyra Biosciences has posted a net loss over the last twelve months (EPS of -$2.63), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Tyra Biosciences
Company profileTyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Todd Harris Ph.D.
- Headquarters
- Carlsbad, CA
- Employees
- 87
- IPO year
- 2021
- Website
- tyra.bio
Financial highlights
Full financialsTyra Biosciences reported a net loss of $119.9 million, compared with a loss of $86.5 million a year earlier. Diluted earnings per share came in at -$2.01.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-119.95M | $-86.48M | $-69.13M | $-55.33M | $-26.29M |
| EPS (diluted) | $-2.01 | $-1.51 | $-1.62 | $-1.32 | $-1.91 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$47.45+135.83%
- Strong buy 2
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.74 vs $-0.66
- Surprise
- -12.12%
TYRA news
All TYRA newsTyra Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs TYRA |
| URGNUroGen Pharma Ltd. | 27.65 | -12.86% | $1.36B | vs TYRA |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs TYRA |
| PAHCPhibro Animal Health Corporation Class A | 33.29 | -2.32% | $1.35B | vs TYRA |
| NBTXNanobiotix S.A. ADR | 26.50 | -2.98% | $1.35B | vs TYRA |
| NUVBNuvation Bio Inc. Class A | 3.80 | -0.26% | $1.34B | vs TYRA |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs TYRA |
| NRIXNurix Therapeutics Inc. | 12.85 | -5.55% | $1.40B | vs TYRA |
Indexes, lists and sector
Tyra Biosciences stock FAQ
What is Tyra Biosciences's stock price today?
TYRA last traded at $20.12 as of Nov 20, 4:00 PM EST, up 1.98% on the day. Prices are delayed at least 15 minutes.
Who is Tyra Biosciences's CEO?
Dr. Todd Harris Ph.D. is the chief executive officer of Tyra Biosciences Inc., which has about 87 employees.
What is the TYRA 52-week high?
The 52-week high for TYRA is $40.65 and the 52-week low is $18.25. The stock is currently 50.5% below its high.